Neohesperidin, a flavonoid compound found in high amounts in Poncirus trifoliata, has free radical scavenging activity. For the first time, our study indicated that neohesperidin also induces cell apoptosis in human breast adenocarcinoma MDA-MB-231 cells, which was possibly mediated by regulating the P53/Bcl-2/Bax pathway. MDA-MB-231 cells were subjected to treatment with neohesperidin. MTT and Trypan blue exclusion assays were applied to assess the cell viability. The morphological changes of cells were observed using an inverted microscope, and cell apoptosis was detected by flow cytometric analysis. Immunoblot analysis was conducted to evaluate the protein expressions of apoptosis-related genes, including P53, Bcl-2 and Bax. Our results indicated that the proliferation of MDA-MB-231 cells was inhibited by the treatment with neohesperidin in a time-and dose-dependent manner. The IC 50 values of neohesperidin at 24 and 48 h were 47.4±2.6 μM and 32.5±1.8 μM, respectively. The expressions of P53 and Bax in the neohesperidin-treated cells were significantly up-regulated, while that of Bcl-2 was down-regulated. Our study suggested that neohesperidin could induce apoptosis of MDA-MB-231 cells, a process which was associated with the activation of the Bcl-2/Bax-mediated signaling pathway.
Breast cancer is one of the primary malignant tumors in the world. In recent years, the incidence of breast cancer has been rapidly rising and remains at the top of the list threatening women's health. The morbidity rate for breast cancer among women rose from 29.99/100, 000 to 68.37/100, 000 from 2002 to 2009 (increased 128%). In China, one out of 1,000 women has breast cancer, and the figure is rising at the rate of 3 to 4 percent a year. At present, the preferred treatment is through surgical removal (preoperative or after surgery assisting with chemotherapy, hormone or radiation therapy), which results in great pain and severe side effects.
MDA-MB-231 is an estrogen receptor-negative (ER-negative) breast cancer cell line, which was derived from a metastatic adenocarcinoma of the mammary gland. This cell line is highly aggressive, invasive and poorly-differentiated [1] . It is a basal type breast cancer cell line (ER-, PR-, HER2-, EGFR+) with expression of mesenchymal markers [2] and widely used in the biomedical studies of this type of cancer. The ER-negative breast cancer, in comparison with the ER-positive subtype, is remarkably lacking in cellular targets. Thus, it cannot be treated effectively with antiestrogen agents, such as tamoxifen, which target the estrogen receptor. Therefore, potential anti-cancer agents to treat ERnegative breast cancer is highly desired.
Chinese herbal medicine has been considered a valuable resource of new pharmaceutical agents. Flavonoids have recently been widely investigated for their anti-oxidant [3] , anti-inflammatory [4] , bacteriostasis [5] and anti-cancer effects [6] . Neohesperidin (Neo) is a plant flavonoid, found in good amount in Poncirus trifoliata (L.) Raf. It has free radical scavenging activity, as well as protective effects on potential gastric diseases [7] . It is one of the important derivatives of hesperidin, with rutinoside on hesperidin replaced by a neohesperidoside. Hesperetin has an inhibitory effect on various cancers, including skin [8] , colon [9] , lung [10] and breast cancers [11] . In particular, a previous study reported that hesperidin can lead to cellular apoptosis in leukemia cell line, HL-60 [12] . Therefore, the derivatives of hesperidin have been hypothesized to have potential anti-tumor effects as well. In the present study, we evaluated molecularly the anti-proliferative effect of neohesperidin on MDA-MB-231 cells, which might become a new lead for treatments of ER-negative breast carcinoma. Cell growth inhibition induced by neohesperidin: Initially, the growth inhibition of MDA-MB-231 cells induced by neohesperidin was assessed by MTT assay (Fig 1 A) . Neohesperidin exhibited a remarkable inhibitory effect on the growth of MDA-MB-231 cells, with IC 50 values at 24 and 48 h of 47.4±2.6 μM and 32.5±1.8 μM, respectively. In addition, Trypan blue staining and cell counting results showed that the number of living cells declined significantly after treatment with neohesperidin for 24 and 48 h (Fig 1 B) . Our results indicated that neohesperidin has an inhibitory effect on breast adenocarcinoma MDA-MB-231 cells in a time-and dosedependent manner. 
Morphological changes of cells induced by neohesperidin:
To further explore the inhibitory effect of neohesperidin on MDA-MB-231 cells, representative images of them were captured by optical microscopy (Figure 3 ). Cell morphological changes started to show after treatment with neohesperidin at 60 µM for 24 h and 20 µM for 48 h. Cell shrinkage and pyknosis were observed by light microscopy. The cells were smaller in size and the cytoplasm was dense. The cells appeared as a round or oval mass with dense purple nuclear chromatin fragments. Previous studies showed that dietary flavonoids can inhibit proliferation and induce apoptosis in many types of tumor cells, including breast, lung, colon and prostate cancer cells [16] [17] [18] . Neohesperidin, a natural flavonoid, has been investigated recently for its antioxidant, anti-inflammatory and bacteriostasis activities, but minimal information was available about its anti-cancer effect.
In this study, we first reported that neohesperidin could inhibit the growth and induce apoptosis of breast cancer MDA-MB-231 cells (Figures 1 and 3 ). Such observation was also supported by the cell morphological changes after treatment with neohesperidin ( Figure 3) . To explore further the molecular mechanism of neohesperidin induced apoptosis in MDA-MB-231 cells, the expressions of essential apoptotic proteins, in particular P53, Bcl-2 and Bax, were assessed (Fig 4) . Our results showed the significantly up-regulated expressions of P53 and Bax, as well as the remarkably downregulation of Bcl-2 in the cells treated with neohesperidin for 24 h. P53 is a tumor suppressor protein, which plays a critical role in the cellular response to DNA damage and other genomic aberrations, including apoptosis regulation [19] . Bcl-2 is an apoptosis inhibitor, which mainly inhibits the mitochondrial apoptosis signaling pathway; while Bax is an apoptotic protein, which is one of the transcriptional targets of P53 [20] [21] [22] . The expression of these three apoptosis regulating factors is essentially related to the apoptosis of breast carcinoma cells [23] [24] [25] . However, it was noted that the P53 in the MDA-MB-231cells is a mutant form of P53, which has been reported to be dysfunctional [26] . Therefore, the increased expression of P53 might not be the direct lead to the cellular apoptosis induced by neohesperidin.
It was previously reported that a high Bcl-2 level was required for maintaining cellular gene transfer and manipulations due to blocking apoptosis [27] . The Bcl-2-homogolous protein, Bax promotes cell apoptosis by competing with Bcl-2. When the level of Bax is low, induction of apoptosis may require up-regulation of Bax expression. If the Bax level is constitutively high, an alternative transactivation of the P53-independent apoptosis pathway might be revealed [28] . Therefore, a change in the ratio of Bax/Bcl-2 determines the cell susceptibility to apoptosis [29, 30] . In our study, the neohesperidin treatment resulted in an elevated Bax/Bcl-2 ratio, which corresponded with the onset of MDA-MB-231 cell apoptosis. Thus our observations indicated that the neohesperidininduced apoptosis in MDA-MB-231 cells was possibly associated with the Bcl-2/Bax mediated signaling pathway.
In summary, our study indicated that neohesperidin induced the apoptosis of ER-negative breast adenocarcinoma MDA-MB-231 cells, the process of which was associated with activation of the Bcl-2/Bax-mediated signaling pathway. Further experiments will be required to investigate the application of neohesperidin in the clinical treatment of ER-negative breast cancer.
Experimental

Drugs and reagents:
Neohesperidin was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Fetal bovine serum (FBS) and RPMI medium 1640 were obtained from Gibco (Life Technologies, USA). 3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), trypan blue, dimethyl sulfoxide (DMSO), sodium bicarbonate, penicillin-streptomycin, trypsin and nitrocellulose paper membrane were obtained from Beyotime (Nantong, China). The monoclonal antibodies used in this study were: P53, Bcl-2, and Bax (Cell Signaling Technology, MA, USA), β-tubulin (Santa Cruz, CA, USA), HRP conjugated goat anti rabbit secondary antibody and BeyoECL Plus (Beyotime, Nantong, China). Annexin V-FITC and PI double staining kit were from PharMingen (San Diego, CA, USA).
Cell culture:
Human MDA-MB-231 breast carcinoma cells were obtained from the American Tissue Culture Collection. MDA-MB-231 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37℃ in a humidified atmosphere containing 5% CO2.
Growth inhibition assays:
The inhibition of cell growth was determined by MTT and Trypan blue exclusion assays. MDA-MB-231 cells were seeded in 96-well microplates (5×10 3 cells/mL). After 24 h incubation, the cells were treated with neohesperidin in serial concentrations and re-incubated for 24 or 48 h. Following incubation, tetrazolium dye (MTT) was added to each well and reincubated for an additional 2 h. Then DMSO was added to dissolve the formazan crystals. Optical density (OD) was measured at 490 nm with an ELISA plate reader (BioTek, Vermont, USA). In the Trypan blue exclusion assay, cells were washed with PBS twice at the end of the incubation period and trypsinized. The cells were resuspended and subject to trypan blue staining and then cell counting. The experiment was conducted in triplicate and the results are indicative of 3 independent studies.
Cellular morphological observation:
MDA-MB-231 cells, collected in the logarithmic stage of growth, were digested into a single cell suspension with trypsin. The cell suspension was dispensed into a 6-well plate (8×10 4 cells/well) and incubated for 24 h. Different concentrations of neohesperidin were added and reincubated for either 24 or 48 h. The morphological changes of MDA-MB-231 cells were observed with an inverted microscope.
Flow cytometry (FCM) assay of apoptosis:
MDA-MB-231 cells were plated in 24-well plates and incubated either in the absence or presence of various concentrations of neohesperidin. After 24 h, the cells were collected and washed with ice-cold PBS, followed by the incubation of Annexin V-FITC on ice for 15 min. Propidium iodide (PI) was added freshly right before the analysis of FCM (FACScan Becton-Dickinson, CA, USA). 10,000 cells were counted, per sample. The apoptotic cells were determined and analyzed with CellQuest software (Becton Dickinson, CA, USA) [13] . concentration was determined by the Bradford method [14] and Western blot analysis was performed as described before [15] . Briefly, the immunoblot was incubated with specific primary antibody against P53 (1:1000), Bcl-2 (1:1000) and Bax (1:2000) (Cell signaling technology, MA, USA) at 4℃ overnight and then incubated for 1 h with HRP-conjugated secondary antibody at room temperature for 1 h. Bound antibodies were detected with BeyoECL Plus (Beyotime, Jiangsu, China). β-Tubulin was used as the loading control.
Western blot analysis
Statistical analysis:
Biostatistical analyses were conducted with the Prism 5.0 and SPSS 16.0 software package. Results of 3 experiments were expressed as mean±SD. A P value less than 0.05 was accepted as statistically significant.
